Mannose-binding lectin-deficient genotypes as a risk factor of pneumococcal meningitis in infants

PLoS One. 2017 May 31;12(5):e0178377. doi: 10.1371/journal.pone.0178377. eCollection 2017.

Abstract

Objectives: The objective of this study was to evaluate to evaluate the role of mannose-binding-lectin deficient genotypes in pneumococcal meningitis (PM) in children.

Methods: We performed a 16-year retrospective study (January 2001 to March 2016) including patients ≤ 18 years with PM. Variables including attack rate of pneumococcal serotype (high or low invasive capacity) and MBL2 genotypes associated with low serum MBL levels were recorded.

Results: Forty-eight patients were included in the study. Median age was 18.5 months and 17/48 episodes (35.4%) occurred in children ≤ 12 months old. Serotypes with high-invasive disease potential were identified in 15/48 episodes (31.2%). MBL2 deficient genotypes accounted for 18.8% (9/48). Children ≤ 12 months old had a 7-fold risk (95% CI: 1.6-29.9; p < 0.01) of having a MBL2 deficient genotype in comparison to those > 12 months old. A sub-analysis of patients by age group revealed significant proportions of carriers of MBL2 deficient genotypes among those ≤ 12 months old with PM caused by opportunistic serotypes (54.5%), admitted to the PICU (Pediatric Intensive Care Unit) (46.7%) and of White ethnicity (35.7%). These proportions were significantly higher than in older children (all p<0.05).

Conclusions: Our results suggest that differences in MBL2 genotype in children ≤12 months old affects susceptibility to PM, and it may have an important role in the episodes caused by non-high invasive disease potential serotypes.

MeSH terms

  • Female
  • Genetic Predisposition to Disease*
  • Genotype*
  • Humans
  • Infant
  • Male
  • Mannose-Binding Lectin / genetics*
  • Meningitis, Pneumococcal / diagnosis
  • Meningitis, Pneumococcal / genetics*
  • Retrospective Studies
  • Risk Factors

Substances

  • Mannose-Binding Lectin

Grants and funding

This work was supported by the Spanish Ministerio de Economía y Competitividad (Plan Nacional de I+D+i, SAF2013-46151-R) (http://www.mineco.gob.es/); Instituto de Salud Carlos III (ISCIII) - co-financed by European Development Regional Fund "A way to achieve Europe" ERDF- (Grant PI13/01729) (http://www.isciii.es/) (http://ec.europa.eu/regional_policy/en/funding/erdf/) and the Spanish Network for Research in Infectious Diseases (REIPI, RD12/0015/0018) (http://reipi.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.